Value of circulating insulin-like growth factor–associated proteins for the detection of stage I non–small cell lung cancer John C. Kubasiak, MD, Christopher.

Slides:

Advertisements

Similar presentations

A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non–small cell lung cancer Babatunde A. Yerokun, MD, Chi-Fu.

Advertisements

Stephen R. Broderick, MD, MPHS

Two decades of pediatric lung transplant in the United States: Have we improved? Farhan Zafar, MD, Jeffrey S. Heinle, MD, Marc G. Schecter, MD, Joseph.

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

Michael Y. Chang, MD, MPH, Steven J. Mentzer, MD, Yolonda L

Characteristics and outcomes of secondary nodules identified on initial computed tomography scan for patients undergoing resection for primary non–small.

A novel detection method of non–small cell lung cancer using multiplexed bead-based serum biomarker profiling Hyun Joo Lee, MD, PhD, Young Tae Kim, MD,

How do cells talk to each other

Serum Biomarkers May Prognosticate Recurrence in Node-Negative, Non-Small Cell Lung Cancers Less Than 4 Centimeters Christopher W. Seder, MD, Andrew.

Local recurrence after surgery for non–small cell lung cancer: A recursive partitioning analysis of multi-institutional data Chris R. Kelsey, MD, Kristin.

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

Preresection serum C-reactive protein measurement and survival among patients with resectable non–small cell lung cancer Marco Alifano, MD, PhD, Pierre.

Does the method of radiologic surveillance affect survival after resection of stage I non– small cell lung cancer? Traves D. Crabtree, MD, Varun Puri,

Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M

Vascular endothelial growth factor C complements the ability of positron emission tomography to predict nodal disease in lung cancer Farhood Farjah,

“Lead from the front”: Participative leadership

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system Shamus R.

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

Ground glass opacity of the lung: The veil that needs lifting

Establishment of a Multi-Analyte Serum Biomarker Panel to Identify Lymph Node Metastases in Non-small Cell Lung Cancer Jeffrey A. Borgia, PhD, Sanjib.

Rate of increase in serum lactate level risk-stratifies infants after surgery for congenital heart disease Kurt R. Schumacher, MS, MD, Rebecca A. Reichel,

Joshua E. Rosen, BASc, Michelle C

Angiogenesis Biomarkers May Be Useful in the Management of Patients With Indeterminate Pulmonary Nodules Christopher W. Seder, MD, John C. Kubasiak,

William M. DeCampli, MD, PhD

Go on-pump or off-pump in diabetic patients?

David D. Shersher, MD, Michael S

Metformin exposure is associated with improved progression-free survival in diabetic patients after resection for early-stage non–small cell lung cancer

Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.

The National Surgical Quality Improvement Program risk calculator does not adequately stratify risk for patients with clinical stage I non–small cell.

The lord of the rings Antonio Miceli, MD, PhD

Is tissue the issue? Brian E. Louie, MD, MHA, MPH, FRCSC, FACS

Treatment trends in early-stage lung cancer in the United States, 2004 to 2013: A time- trend analysis of the National Cancer Data Base Kathryn E. Engelhardt,

Yang Zhang, MD, Haiquan Chen, MD, PhD

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Circulating Angiogenesis Biomarkers Are Associated With Disease Progression in Lung Adenocarcinoma Shaun Daly, MD, John C. Kubasiak, MD, Daniel Rinewalt,

Fixing the supply problem

Management of stage IIIA (N2) non–small cell lung cancer: A transatlantic perspective Gaetano Rocco, MD, Katie Nason, MD, MPH, Alex Brunelli, MD, Gonzalo.

A first start for lung transplantation?

Stephen R. Broderick, MD, MPHS

Joseph A. Dearani, MD, Michael J. Ackerman, MD, PhD

Yusuke Takahashi, MD, PhD, Prasad S. Adusumilli, MD

Resection of primary lung cancer with incidental pleural seeding: Seeds of change or reap what you sow? Jules Lin, MD The Journal of Thoracic and Cardiovascular.

Niv Ad, MD, Lawrence M. Wei, MD

Instrumental variable methods in clinical research

Attachment disorder in thoracoabdominal surgery

Marc Licker, MD, John Diaper, RA

Uma M. Sachdeva, MD, PhD, Daniela Molena, MD

Internal validation of risk models in lung resection surgery: Bootstrap versus training- and-test sampling Alessandro Brunelli, MD, Gaetano Rocco, MD

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Metabolomics study of esophageal adenocarcinoma

Bryan M. Burt, MD The Journal of Thoracic and Cardiovascular Surgery

Jeffrey H. Shuhaiber, MD, Jeff Moore, MS, David B. Dyke, MD

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

The future of cardiac surgery training: A survival guide

Robert J. Cerfolio, MD, FACS, FCCP, Ayesha S. Bryant, MSPH, MD

Reliability of risk algorithms in predicting early and late operative outcomes in high-risk patients undergoing aortic valve replacement Todd M. Dewey,

Vinay Badhwar, MD, John S. Ikonomidis, MD, PhD, Jeffrey P. Jacobs, MD

“The more things change…”: The challenges ahead

Large clinical databases for the study of lung cancer: Making up for the failure of randomized trials Chi-Fu Jeffrey Yang, MD, Matthew G. Hartwig, MD,

Why arch curvature affects arch resistance

Aritoshi Hattori, MD, Kenji Suzuki, MD

Who should decide margin length in pulmonary excision of lung cancer?

Is there a benefit to continuing with resection of all sites of disease when clinically occult pleural metastases from non–small cell carcinoma are found?

Samuel Kim, MD The Journal of Thoracic and Cardiovascular Surgery

Impact of neoadjuvant chemoradiotherapy followed by surgical resection on node- negative T3 and T4 non–small cell lung cancer Benedict D.T. Daly, MD,

MiR-1254 and miR-574-5p: Serum-Based microRNA Biomarkers for Early-Stage Non- small Cell Lung Cancer Kristen M. Foss, BS, Chao Sima, PhD, Donatella Ugolini,

Reappraise the advanced technique for tumor localization and sentinel lymph node assessment in clinical early-stage non–small cell lung cancer Chengwu.

Presentation transcript:

Value of circulating insulin-like growth factor–associated proteins for the detection of stage I non–small cell lung cancer John C. Kubasiak, MD, Christopher W. Seder, MD, Ravi Pithadia, MD, Sanjib Basu, PhD, Cristina Fhied, MS, William W. Phillips, BS, Shaun Daly, MD, David D. Shersher, MD, Mark A. Yoder, MD, Gary Chmielewski, MD, Eric S. Edell, MD, Fabien Maldonado, MD, Michael J. Liptay, MD, Jeffrey A. Borgia, PhD The Journal of Thoracic and Cardiovascular Surgery Volume 149, Issue 3, Pages 727-734.e3 (March 2015) DOI: 10.1016/j.jtcvs.2014.08.085 Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Illustration of the experimental workflow. A, The workflow for the serum-based biomarker evaluation phase. B, The workflow for the plasma-based multianalyte algorithm development. C, The validation phase. Luminex Corp (Austin, Tex). NSCLC, Non–small lung cancer. The Journal of Thoracic and Cardiovascular Surgery 2015 149, 727-734.e3DOI: (10.1016/j.jtcvs.2014.08.085) Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Representative box and whisker plots illustrating distributions and differences in biomarkers. Four representative plots are provided to permit an appreciation of serum biomarker distributions between the combined Rush and Mayo cohorts for patients with either a benign nodule (n = 123) or malignant nodule (n = 224). Significance is indicated by a bar with “1” indicating P ≤ .001; “2” meaning P < .01; and “3” meaning P < .05. Not all extreme values are represented on the provided plots. IGF, Insulin-like growth factor; IGFBP, insulin-like growth factor binding protein. The Journal of Thoracic and Cardiovascular Surgery 2015 149, 727-734.e3DOI: (10.1016/j.jtcvs.2014.08.085) Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

Figure E1 Receiver operator characteristics curves from the multianalyte algorithm validation. Illustrated is the performance of the 7-analyte panel against the Mayo Clinic (ie, validation) cohort. The panel is composed of interleukin (IL)-6, IL-10, IL-1ra, stromal cell-derived factor-1α + β, insulin-like growth factor binding protein-5, and insulin-like growth factor-2. AUC, Area under the curve. The Journal of Thoracic and Cardiovascular Surgery 2015 149, 727-734.e3DOI: (10.1016/j.jtcvs.2014.08.085) Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions